Efficacy Versus Ointment

Enstilar® is more effective than Dovobet ointment* in achieving treatment success at week 41

how Enstilar affects psoriasis compare dovobet

Adapted from Koo J et al. J Dermatolog Treat 2016

Koo J et al., 2016:A multicentre, investigator-blinded Phase II study. Treatment success was defined as patients who achieved clear or almost clear skin with at least a two-step improvement according to PGA. 54.6% (n=77/141) of patients using Enstilar® achieved treatment success by week 4 vs 43.0% (n=58/135) using Dovobet ointment* (p=0.025).1

CI: confidence interval; OR: odds ratio; PGA: physician’s global assessment.

UK Enstilar® foam and Dovobet® ointment cost comparison:3

Pack sizeTreatmentBasic NHS Price
60 gEnstilar® foam£39.68
Dovobet® ointment£39.68
2 x 60 g
(120 g)
Enstilar® foam£79.36
Dovobet® ointment£73.86

Are you still using
Dovobet® ointment?

Optimise your patient’s treatment
and advance them to Enstilar®

Return to the efficacy overview
See the difference in real-world patients

*Dovobet® ointment is not available in Ireland

LEO Pharma Product Licence Indications
Enstilar® is indicated for the topical treatment of psoriasis vulgaris in adults.1  Prescribing information can be found here
Dovobet® ointment is indicated for the topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy in adults. Prescribing information can be found here
Dovobet® gel is indicated for scalp psoriasis in adults and the topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults.3.  Prescribing information can be found here

  1. Koo J et al. J Dermatolog Treat2016; 27(2):120–127.
  2. King C et al.Poster 237 presented at the 5th Psoriasis International Network Annual Meeting, Paris, France, 5–7 July 2016.
  3. BNF formulary. https://www.medicinescomplete.com/mc/bnf/current/. Last accessed July 2019.
MAT-25467 September 2019

Keep in touch with LEO Pharma

Latest product information, consultation tools, hot topics in dermatology and congress updates.  Be the first to know with LEO Pharma. Sign up

MAT-29941 November 2019

Holler Box